TALTZ

Product NDC: 0002-8900
11-digit product format: 000028900
Labeler code: 0002
Product ID: 0002-8900_246fceb3-0f60-4bd7-8f06-4f34537f5d95
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: ixekizumab
Dosage form: INJECTION, SOLUTION
Route: SUBCUTANEOUS
Labeler: Eli Lilly and Company
Application: BLA125521
Marketing category: BLA
Marketing start: 2016-03-22
Substance: IXEKIZUMAB
Active strength: 20 mg/.25mL
Pharmacologic classes: Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]
NDC exclude flag: No
Listing certified through: 2026-12-31
Current FDA listing: Yes

openFDA Listing Details

Product ID: 0002-8900_246fceb3-0f60-4bd7-8f06-4f34537f5d95
SPL ID: 246fceb3-0f60-4bd7-8f06-4f34537f5d95
Product type: HUMAN PRESCRIPTION DRUG
Finished product: Yes
Brand name base: TALTZ
Generic name: ixekizumab
Dosage form: INJECTION, SOLUTION
Route: SUBCUTANEOUS
Marketing start: 2016-03-22
Marketing category: BLA
Application number: BLA125521
Pharmacologic classes: Interleukin-17A Antagonist [EPC]; Interleukin-17A Antagonists [MoA]
Listing expiration: 2026-12-31

Ingredient	Strength
IXEKIZUMAB	20 mg/.25mL

Package NDC	Description	Marketing start	Sample
0002-8900-11	1 SYRINGE in 1 CARTON (0002-8900-11) / 1 mL in 1 SYRINGE (0002-8900-01)	2024-02-02	No

UNII	Preferred term	Registry number	Matched term
BTY153760O	IXEKIZUMAB	1143503-69-8	IXEKIZUMAB

Package NDC	11-digit format	Description	Units	Marketing start	Sample	Exclude flag	Status
0002-8900-11	00002890011	1 SYRINGE in 1 CARTON (0002-8900-11) / 1 mL in 1 SYRINGE (0002-8900-01)	1 syringe	2024-02-02	No	No	Historical

Title	Manufacturer	Effective date	Type	Version
TALTZ	Eli Lilly and Company	2024-11-13	HUMAN PRESCRIPTION DRUG LABEL	39